Compare Macy's Inc (M) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Macy's Inc vs Sanofi SA — how do they compare? Macy's Inc trades at $22.79 (market cap $5.95B), while Sanofi SA trades at $40.1 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 16× Macy's Inc's market cap, and Sanofi SA pays the higher dividend (6.01%). Which is the better fit depends on your goals — on Pluang, investors hold Macy's Inc for 58 Days and Sanofi SA for 94 Days on average.
| M | SNY | |
|---|---|---|
Market Cap | $5.95B | $95.18B |
Volume | 6,030,644 | 2,995,646 |
Sector | Consumer Cyclical | Health |
52-Week High | $26.21 | $52.34 |
52-Week Low | $16.51 | $39.51 |
Typical Hold Time | 58 Days | 94 Days |
Enterprise Value | $9.75B | $114.48B |
Dividend Yield | 3.36% | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Macy's stock trades at $22.79, up 1.47% today, with a bullish technical signal supported by moving averages. The company shows improving fundamentals, with Q2 2026 EPS beating estimates and a raised 2026 outlook. Valuation remains attractive with a P/E of 8.35 and P/S of 0.27, while cash flow trends have strengthened, with net cash flow turning positive in 2024 and 2025. Recent news highlights progress in the 'Bold New Chapter' strategy, focusing on digital and omnichannel growth.
The outlook for Macy's is cautiously optimistic, supported by cheap valuations and strategic initiatives, but risks include competitive pressures and uneven earnings growth. Analyst consensus is mixed with a $24.25 price target, indicating modest upside potential. Key investment opportunities lie in dividend yield and turnaround execution, while risks involve margin pressure and macroeconomic headwinds affecting retail demand.
SNY trades at $40.2, up 1.62% on the day, with a bearish technical signal from moving averages but a neutral oscillator stance. The company reported revenue of $46.72B in 2025 with a net income margin of 16.72%, and it has beaten EPS estimates for the last three quarters. Recent news highlights a significant $8B immunology alliance expansion with Regeneron, signaling strong pipeline development.
The outlook is mixed; analyst consensus leans hold (51.86%) with a buy rating at 44.44%, reflecting optimism on new drug launches but caution over future profit margin compression projected for 2026. Key risks include execution of the expanded Regeneron partnership and managing debt levels amid investing cash flow volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Macy's Inc
Founded in 1858 and based in New York City, Macy's operates 570 stores under the Macy's nameplate, 58 stores under the Bloomingdale's nameplate, and 160 freestanding Bluemercury specialty beauty stores (as of the end of fiscal-year 2021). Macy's also operates e-commerce sites and licenses two Bloomingdale's stores in the United Arab Emirates and Kuwait. Women's apparel, accessories, shoes, cosmetics, and fragrances comprised 59% of Macy's 2021 sales.
Read more on M →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
